Business
Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market
Leading OTF Manufacturer CURE Pharmaceutical Comments on New Report Showing Exponential Growth in Thin Film Drug Manufacturing Market.
About this update from Avenir Wellness Solutions Inc.
[{"type":"text","content":"\n\n OXNARD, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- CURE Pharmaceutical (OTCQB:CURR), (“CURE”), a leading disruptive drug delivery technology and pharmaceutical cannabinoid molecule development company, is commenting today on a new research report by Transparency Market Research (TMR) that predicts the global thin film drug manufacturing market to be worth US $15.9 billion by the end of 2024.\n According to the research report, the global market for thin film drug manufacturing will experience a compound annual growth rate (CAGR) of 9 percent from US $7.3 billion in 2015 to $15.9 billion by the end of 2024. The report also estimates the North American thin film manufacturing market, which accounted for a share of more than 66.6 percent in 2016, to emerge as a leading regional market. The report states that the growing demand for efficient drug delivery systems has augmented the uptake of thin film drugs due to their efficiency and effectiveness, with the convenience of transportation and storage encouraging patients to opt for these drugs. “As the pre-eminent developer and manufacturer of the most advanced oral thin film (CureFilm™) on the market today, we are extremely encouraged by this new research report market and believe CURE is poised and well-positioned to play a leading role in this market moving forward,” said Rob Davidson, CEO of CURE Pharmaceutical. “As the report indicates, we see continued growth in this market as the healthcare industry continues to adopt groundbreaking drug delivery technologies such as OTF products, given their multitude of benefits including convenient administration, increased bioavailability and greater patient compliance.” CURE Pharmaceutical’s patented, multilayer oral thin film, CureFilm™, is designed for oral administration. Without the need for water, it delivers medications to the tongue, cheek or sublingual regions of the mouth, allowing the medication to enter the blood stream enterically, buccally, or sublingually. CureFilm™ has been developed to improve upon the pharmacokinetic profile and the overall therapeutic index of an Active Pharmaceutical Ingredient (API). CureFilm™ technology enables delivery of higher doses of medications with better flavor masking. CURE Pharmaceutical recently announced the pub...